HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Analyst Earnings Estimates
EBR:HYL - Euronext Brussels - BE0974363955 - Common Stock - Currency: EUR
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 900K -70.93% | 2.087M 131.89% | 8.458M 305.27% | 17.827M 110.77% | 33.583M 88.38% | 108.07M 221.80% | |
| EBITDA YoY % growth | -11.312M -11.01% | -15.497M -37.00% | -5.721M 63.08% | -11.985M -109.50% | 4.006M 133.42% | 60.297M 1,405.17% | |
| EBIT YoY % growth | -11.508M -11.44% | -15.846M -37.70% | -6.369M 59.81% | -7.272M -14.18% | 26.21M 460.42% | 59.085M 125.43% | |
| Operating Margin | -1,278.67% | -759.27% | -75.30% | -40.79% | 78.05% | 54.67% | |
| EPS YoY % growth | N/A -2.27% | N/A -26.67% | N/A 2.34% | -0.42 25.75% | -0.54 -28.23% | 1.61 400.00% |
All data in EUR
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | 4.305M 364.40% | % | ||
| Q2 2024 Q2Q % growth | 4.153M 576.38% | % | ||
| Q4 2023 Q2Q % growth | 927K 3.00% | % | ||
| Q2 2023 Q2Q % growth | 614K -40.56% | % | ||
| Q4 2022 Q2Q % growth | 900K -60.14% | % | ||
| Q2 2022 Q2Q % growth | 1.033M 23.27% | % | ||
| Q4 2021 Q2Q % growth | 2.258M 2,327.96% | % | ||
| Q2 2021 Q2Q % growth | 838K 4,310.53% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | 0% | 0% |
| Revenue | N/A | N/A | 0% | -24.89% |